鸿茅药酒品牌怎么样 申请店铺

我要投票 鸿茅药酒在保健酒行业中的票数:428 更新时间:2025-07-07
鸿茅药酒是哪个国家的品牌?「鸿茅药酒」是内蒙古鸿茅国药股份有限公司旗下著名品牌。该品牌发源于内蒙古,由创始人鲍洪升在2002期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力鸿茅药酒品牌出海!将品牌入驻外推网,定制鸿茅药酒品牌推广信息,可以显著提高鸿茅药酒产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

鸿茅药酒怎么样

内蒙古鸿茅药业有限责任公司成立于2002年,其前身为内蒙古凉城县鸿茅酒厂。公司现有职工300余名,总资产超过2亿,生产基地占地280余亩,拥有药酒、保健酒等多个品种。

公司主营产品“鸿茅药酒”,始创于1739年(清乾隆四年),距今已经有近三百年的历史。曾作为宫廷贡酒,被封为皇室养生益寿的御用圣品,传承数百年药用历史,成为中华医药的瑰宝,并入选国家“非物质文化遗产名录”。

2011年,中华人民共和国商务部授予鸿茅为“中华老字号”;2011年,国家工商行政管理总局认定鸿茅为“驰名保护”;2014年“鸿茅药酒配制技艺”入选国务院批准文化部确定的《第四批非物质文化遗产代表性项目名录》。

新一代鸿茅人谨遵“良药济世,精工取繁”的百年祖训,结合传统“八步古法酿造工艺”和现代高科技萃取技术,创新开发出符合GMP标准的现代化工艺—20级精制法,不断提升药酒的品质,从源头上保证消费者的权益。

“使命民族企业,成就中华瑰宝”是鸿茅药业的企业发展理念,以文化为先导,以品质为核心,鸿茅药业坚守“仁、道、信、义、至善”的核心价值观,全面提升企业的新技艺研发能力,推动创新实效的企业运营模式,通过持续的品牌建设和创新营销,践行“百年鸿茅”的企业目标,做中医药文化的传播者。

新时期的鸿茅人正意气奋发地投身搏击于中国的经济大潮,依托于健康中国的发展机遇,以更加成就稳健的姿态去迎接这个神圣而艰巨的挑战,续写“百年鸿茅”品牌更辉煌的未来!

Inner Mongolia Hongmao Pharmaceutical Co., Ltd. was founded in 2002, its predecessor is Inner Mongolia Liangcheng Hongmao distillery. The company has more than 300 employees, a total assets of more than 200 million, a production base covering an area of more than 280 mu, with a variety of medicine wine, health wine and so on. The company's main product, "Hongmao medicinal wine", was founded in 1739 (the fourth year of Qianlong in the Qing Dynasty). It has a history of nearly 300 years. As a royal tribute wine, it was awarded as a Royal Saint for health preservation and longevity, inheriting hundreds of years of medicinal history, becoming a treasure of Chinese medicine and listed in the national intangible cultural heritage list. In 2011, the Ministry of Commerce of the people's Republic of China Awarded Hongmao as the "time-honored brand of China"; in 2011, the State Administration for Industry and Commerce recognized Hongmao as "well-known protection"; in 2014, "Hongmao liquor preparation technology" was selected into the "fourth batch of Intangible Cultural Heritage Representative project list" approved by the Ministry of culture. A new generation of Hongmao people, following the centenary motto of "good medicine for the world, precision work for the complex", combined with the traditional "eight step ancient brewing process" and modern high-tech extraction technology, have innovated and developed a modern process - 20 level refining process that meets the GMP standard, constantly improving the quality of medicinal wine, and ensuring the rights and interests of consumers from the source. "Mission of national enterprises, achievement of Chinese treasures" is Hongmao pharmaceutical's enterprise development concept, taking culture as the guide, quality as the core, Hongmao pharmaceutical adheres to the core values of "benevolence, Taoism, faith, righteousness, and supreme goodness", comprehensively improves the enterprise's new technology research and development ability, promotes the innovative and effective enterprise operation mode, and practices "one hundred years" through continuous brand building and innovative marketing Hongmao "aims to be a disseminator of traditional Chinese medicine culture. In the new era, Hongmao people are devoting themselves to the economic tide of China, relying on the development opportunity of healthy China, meeting this sacred and arduous challenge with a more stable attitude of achievement, and continuing to write a more brilliant future of "Hongmao" brand!

本文链接: https://brand.waitui.com/331f518f1.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

蓝思科技香港上市定价为发行区间上限,募资6.07亿美元

苹果公司供应商蓝思科技将其香港上市定价设定在发行区间上限,募资48亿港元(约合6.07亿美元)。条款显示,这家在深圳上市的公司以每股18.18 港元的价格发售了2.623亿股股票。蓝思科技此次的发行价区间为每股17.38港元至18.18港元。每股18.18港元的定价,较蓝思科技上周五23.74元人民币的收盘价折让30%。(新浪财经)

18分钟前

合合信息:中国证监会接收公司发行境外上市股份备案申请材料

36氪获悉,合合信息公告,公司已于2025年6月26日向香港联合交易所有限公司递交了发行H股股票并在香港联交所主板挂牌上市的申请,并于同日在香港联交所网站刊登了本次发行的申请资料。公司根据相关规定已向中国证券监督管理委员会报送了本次发行上市的备案申请材料,并于近日获中国证监会接收。

18分钟前

欧元区5月零售贸易额环比下降0.7%

当地时间7月7日,欧盟统计局发布的数据显示,经季节性调整后,今年5月欧元区零售贸易额环比下降0.7%,欧盟零售贸易额环比下降0.8%。(央视新闻)

18分钟前

宁波能源:拟投资2.4亿元设立参股公司

36氪获悉,宁波能源公告,公司与浙江海风、日月股份、东方电缆共同发起设立项目公司,负责投资建设浙江(华东)深远海风电母港象山基地项目。项目公司注册资本为12亿元,宁波能源认缴注册资本金为2.4亿元,股权占比20%。本次投资不纳入公司合并报表范围。

18分钟前

华友钴业:上半年净利润同比预增55.62%-67.59%

36氪获悉,华友钴业公告,预计2025年半年度实现归属于母公司所有者的净利润26亿元到28亿元,同比增加55.62%到67.59%。业绩预增主要受益于公司产业一体化经营优势的持续释放、钴价的回升、公司管理变革、降本增效的深入推进。

18分钟前

本页详细列出关于鸿茅药酒的品牌信息,含品牌所属公司介绍,鸿茅药酒所处行业的品牌地位及优势。
咨询